Physician profile
James E Carly
NPI 1316240575
$3,795.19
in general payments reported to CMS, 2019-2025
19 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $678 · 2022: $881 · 2023: $920 · 2024: $639 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.41 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $651.92 | 2021-2025 | |
| Ucb, INC. | $608.43 | 2021-2025 | Bimzelx |
| Pfizer INC. | $414.34 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $337.03 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $314.43 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $252.29 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $221.79 | 2023-2024 | Vtama |
| Biofrontera INC. | $175.06 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Biotech, INC. | $146.24 | 2021-2024 | Tremfya, Simponi, Stelara |
| Leo Pharma INC. | $140.80 | 2022-2025 | Adbry |
| Organon LLC | $135.88 | 2021-2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $122.10 | 2021-2023 | |
| Genzyme Corporation | $68.40 | 2022-2023 | |
| Galderma Laboratories, L.P. | $63.58 | 2021-2024 | Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.97 | 2021-2025 | Cabtreo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $24.20 | 2022 | |
| Strata Skin Sciences, INC. | $23.38 | 2025 | Xtrac |
| Arcutis Biotherapeutics, INC. | $16.98 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $16.37 | 2023 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Carly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.